Evidera and CSS partner on patient-centric research development

23rd August 2019 (Last Updated December 22nd, 2019 15:23)

Evidera has reached an exclusive collaboration agreement with Shin Nippon Biomedical Laboratories’ (SNBL) subsidiary Clinical Study Support (CSS) to jointly deliver more consulting and analytical capabilities for clinical research.

Evidera has reached an exclusive collaboration agreement with Shin Nippon Biomedical Laboratories’ (SNBL) subsidiary Clinical Study Support (CSS) to jointly deliver more consulting and analytical capabilities for clinical research.

The two companies will work on creating a complete geographic customer solution for real-world and patient-centric clinical research.

Evidera provides evidence-based solutions to show the real-world efficacy and safety of health care products.

Japan-based clinical research organisation CSS offers post-market real-world research services, such as database studies and pharmaco-economics.

The companies will use their combined expertise to provide research services to global or Japan-based clients conducting studies which include a Japanese component.

These kinds of clinical services include the design and implementation of real-world studies, qualitative and quantitative patient-centred research, as well as patient recruitment for potential studies.

“This collaboration will allow us to provide broader solutions for our clients as they develop evidence to support regulatory submissions.”

Together, they will also conduct the development of direct-to-electronic medical record (EMR) and EMR-enabled studies in Japan.

CSS founder and CEO Tatsuya Isomura said: “Our collaboration with Evidera allows us to support larger global projects that may benefit from our knowledge and expertise in Japanese-specific settings.

“Our clients will gain access to global project management and operational resources that will enable larger and more complex research programmes, as well as more robust evidence of product value and safety.”

The collaboration also intends to establish a joint office in Japan to facilitate project delivery in an efficient manner.

The companies will continue to explore opportunities to expand their joint capabilities in data analytics and management, biostatistics, epidemiology, and in conducting qualitative research.

Evidera president Karen Kaucic said: “This collaboration will allow us to provide broader solutions for our clients as they develop evidence to support regulatory submissions and market access in Japan.”